PCI Pharma Services

World-leading integrated CDMO providing end-to-end drug development, manufacturing, and packaging. 38 sites across 7 countries with 7,500+ employees. Acquired Ajinomoto Bio-Pharma Services in 2025, gaining peptide and oligonucleotide capabilities including AJIPHASE liquid phase synthesis technology. San Diego campus specializes in oligonucleotides, peptides, complex formulations, and sterile fill-finish. Philadelphia headquarters houses Biotech Packaging Center of Excellence. Over 90 successful product launches per year with 50+ years in healthcare services.

PCI Pharma Services is listed as a CDMO in the peptide supply chain, serving North America markets from USA (Philadelphia, PA). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 2 independent sources, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.